Adding Custirsen to Standard of Care Did Not Improve Survival in MCRPC Patients, AFFINITY Trial Shows

Adding Custirsen to Standard of Care Did Not Improve Survival in MCRPC Patients, AFFINITY Trial Shows
Combining custirsen (OGX-011) with Jevtana (cabazitaxel) and prednisone does not improve survival of metastatic castration-resistant prostate cancer (PC) patients who progressed after prior Taxotere (docetaxel) treatment, new Phase 3 clinical data shows. The findings were included in the study, “Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial,” and published in the journal The Lancet Oncology. The results came from  from the AFFINITY Phase 3 trial (NCT01578655), funded by OncoGenex Pharmaceuticals. The research team was led by Tomasz M. Beer, MD, deputy director and chair for PC research at the OHSU Knight Cancer Institute, in Portland, OR. Although treatment with Taxotere and prednisone improves survival in metastatic castration-resistant PC, few treatment strategies are available if this first-line therapy fails. Second-line therapy of anti-cancer agent Jevtana with the steroid medicine prednisone is currently used, with favorable data reported in 2010. However, new options are still needed to improve patients’ survival. Custirsen inhibits the production of
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *